Page 18 - Read Online

Abughanimeh et al. J Cancer Metastasis Treat 2020;6:50 I http://dx.doi.org/10.20517/2394-4722.2020.110 Page 13 of 13

49. Cho DC, Mahipal A, Dowlati A, et al. Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease
small-cell lung cancer (ED-SCLC). J Clin Oncol 2018;36:8517.
50. Owonikoko T, Higgins K, Chen ZJ, et al. A randomized phase II study of tremelimumab and durvalumab with or without radiation for
patients with relapsed small cell lung cancer (SCLC). J Clin Oncol 2019;37:8515.
51. Chiang AC, Sequist LVD, Gilbert J, et al. Clinical activity and safety of Atezolizumab in a phase 1 study of patients with relapsed/
refractory small-cell lung cancer. Clin Lung Cancer 2020;21:455-63.
52. Pujol JL, Lavole A, Quoix E, et al. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously
untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. Ann Oncol 2015;26:908-14.
53. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or
partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group
Study BR.20. J Clin Oncol 2007;25:4278-84.
54. Allen JW, Moon J, Redman M, et al. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and
without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 2014;32:2463-70.
55. Belani CP, Dahlberg SE, Rudin CM, et al. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with
extensive-stage small cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer 2016;122:2371-8.
56. de Marinis F, Atmaca A, Tiseo M, et al. A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients
with small-cell lung cancer. J Thorac Oncol 2013;8:1091-4.
57. Rudin CM, Salgia R, Wang X, et al. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense
oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008;26:870-6.
58. Langer CJ, Albert I, Ross HJ, et al; GEM017 Investigators. Randomized phase II study of carboplatin and etoposide with or without
obatoclax mesylate in extensive-stage small cell lung cancer. Lung Cancer 2014;85:420-8.
59. Melichar B, Adenis A, Lockhart AC, et al. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with
breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal
adenocarcinoma: a five-arm phase 2 study. Lancet Oncol 2015;16:395-405.
60. Yang S, Zhang Z, Wang QM. Emerging therapies for small cell lung cancer. J Hematol Oncol 2019;12:47.
61. Koinis F, Agelaki S, Karavassilis V, et al. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a
multicentre phase II study of the Hellenic Oncology Research Group. Br J Cancer 2017;117:8-14.
62. Cheng Y, Wang Q, Li K, et al. OA13.03 anlotinib as third-line or further-line treatment in relapsed SCLC: a multicentre, randomized,
double-blind phase 2 trial. J Thorac Oncol 2018;13:S351-2.
63. Cheng Y, Wang Q, Li K, et al. Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed
small-cell lung cancer (SCLC). Ann Oncol 2019;30:v710-7.
64. Rogado J, Pangua C, Serrano-Montero G, et al. Covid-19 and lung cancer: a greater fatality rate? Lung Cancer 2020;146:19-22.